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Background: Previous studies have determined the neurochemical metabolite abnormalities 
in major depressive disorder (MDD). The results of studies are inconsistent. Severity of depres-
sion may relate to neurochemical metabolic changes. The aim of this study is to investigate 
neurochemical metabolite levels in the prefrontal cortex (PFC) of patients with mild/moderate 
MDD.
Methods: Twenty-one patients with mild MDD, 18 patients with moderate MDD, and 
16 matched control subjects participated in the study. Patients had had their first episode. They 
had not taken treatment. The severity of depression was assessed by the Hamilton Rating Scale 
for Depression (HAM-D). Levels of N-acetyl aspartate (NAA), choline-containing compounds 
(Cho), and creatine-containing compounds (Cr) were measured using proton magnetic resonance 
spectroscopy (1H-MRS) at 1.5 T, with an 8-cm3 single voxel placed in the right PFC.
Results: The moderate MDD patients had lower NAA/Cr levels than the control group. No 
differences were found in neurochemical metabolite levels between the mild MDD and control 
groups. No correlation was found between the patients’ neurochemical metabolite levels and 
HAM-D scores.
Conclusion: Our findings suggest that NAA/Cr levels are low in moderate-level MDD in the 
PFC. Neurochemical metabolite levels did not change in mild depressive disorder. Our results 
suggest that the severity of depression may affect neuronal function and viability. Studies are 
needed to confirm this finding, including studies on severely depressive patients.
Keywords: major depressive disorder, magnetic resonance spectroscopy, N-acetyl aspartate, 
creatine, choline
Introduction
Major depressive disorder (MDD) is a syndrome that negatively affects a person’s life 
and functionality.1 Functional neuroanatomical and structural magnetic resonance imag-
ing (MRI) studies have shown abnormalities related to emotional processes in brain 
structures in MDD. Volume changes in the prefrontal cortex (PFC), hippocampus, and 
striatum have been reported.2–5 Damage to neurons and glia and decreases in their num-
bers and sizes have been shown in a postmortem study.6 Lorenzetti et al7 have examined 
the structural MRI studies carried out during 2000 and 2007. It has been determined 
that in MDD, volume decrease in hippocampus, basal ganglia, orbitofrontal cortex, and 
PFC is a consistent result. It has especially been observed that regional brain volume 
has been significantly affected in studies evaluating patients with long sickness time 
and repeating episodes. In another systematic review and meta-analysis, publications 
prior to March 2011 have been examined. In this meta-analysis, it has been determined 
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that there is volume decrease in brain regions such as frontal 
cortex, orbitofrontal cortex, cingulated cortex, hippocampus, 
and striatum in unipolar depressive disorder.8
Proton magnetic resonance spectroscopy (1H-MRS) is an 
imaging technique that can be used to measure neurochemical 
structures and the metabolites of tissues noninvasively and 
present them in one spectrum. This technology can be used 
to determine the in vivo levels of neurochemical compounds 
that contain N-acetyl aspartate (NAA), creatine (Cr), and 
choline (Cho) in an evaluated region of interest. NAA is a 
compound that is found in adult neurons and is recognized 
as a marker of neuronal integrity, viability, and/or function.9 
The resonance signal for Cho resonance is composed of 
phosphocholine, glycerophosphocholine, and free Cho. It 
has been argued that high Cho levels result from changes 
in the metabolism of phospholipids in cellular membranes 
and from a high degree of membrane degradation. Total Cr, 
comprised of Cr and phosphocreatine, is a marker of oxidative 
metabolism. The creatine peak is used as a reference value 
because it remains consistent in H-MRS; this use of the Cr 
peak is based on the assumption that Cr resonance is constant 
and is not affected by various pathologies.10
The PFC plays an important role in mood regulation.11 
The number of studies on neurochemical changes that occur 
in the PFC during depression is few and there are conflicting 
results. In patients with melancholic features and excessive 
depressive symptoms, metabolite levels before and after 
electroconvulsive  treatment and pharmacotherapy have been 
examined. It has been determined that glutamate/glutamine 
levels were lower in comparison with the control group and 
that there is a negative correlation with depressive symptom 
severity. It has been emphasized that glutamate/glutamine 
have recovered following a successful treatment and that 
this anomaly is situational.12 The frontal cortex NAA/Cr, 
Cho/Cr, myo-inositol/Cr values in depression patients were 
determined to be lower in comparison with the healthy control 
group. However, the absolute Cr value in the patient group 
was determined to be higher in comparison with the control 
group.13 Coupland et al14 determined that levels of NAA, Cho, 
and Cr in the PFC were normal and myo-inositol levels were 
lower in patients with moderate or severe depressive disorder. 
They concluded that there are glial metabolism changes 
and glial cell loss in MDD. In a study carried out on elderly 
depression patients who have not been taking medication for 
at least 2 weeks, no statistically significant difference was 
determined in the NAA, Cho, Cr, glutamate/glutamine, and 
myo-inositol levels in comparison with the control group.15 In 
patients with chronic pain and depression, it was concluded 
that the lowness of NAA in the right dorsolateral PFC is 
related to depression and not to pain.16
In patients with unipolar depressive disorder, neurochem-
ical metabolite levels such as dorsolateral PFC NAA, Cho, 
and Cr were determined to be similar to those of the healthy 
control group. However NAA/Cr levels were determined to 
be significantly lower in patients with longer sickness time 
in comparison to patients with shorter illness duration.16 It 
has also been reported that the levels of Cr and Cho in the 
hippocampus increase in patients with recurrent depressive 
disorder and this increase is related to both the number of 
depressive episodes and the duration of the disease.17 The 
severity of depression may be a factor that affects the changes 
in the neurochemical metabolite levels that are observed in 
MDD.18–20
The PFC is an important region for the regulation of 
emotion and conflicting results have been obtained in 
1H-MRS studies carried out on this region. Previous studies 
lead one to think that depression severity and recurring 
depressive episodes affect neuronal functions and thus the 
study results. The objective of this study was to examine 
the neurochemical changes that occur on patients with only 
first-episode depression who do not use any medication. It 
is expected that the results obtained will contribute to the 
understanding of the neurochemical changes that occur in 
first-episode depressive disorder.
Methods
Subjects and study procedure
Subjects in this study were patients who were diagnosed 
with first-episode MDD according to diagnostic criteria from 
the Diagnostic and Statistical Manual of Mental Disorders, 
Fourth Edition (DSM-IV).21 This study was carried out 
on patients who had applied to the Pamukkale University 
Faculty of Medicine Psychiatry polyclinic from May 2010 
to May 2011. A diagnostic assessment was performed to rule 
out other major Axis I disorders, including schizophrenia, 
bipolar disorders, and anxiety disorders. All of the patients 
were unmedicated. Subjects completed sociodemographic 
data forms that had been prepared by the researchers. 
Following psychiatric examination, the psychiatrist who was 
conducting the examination assessed the patients using the 
Hamilton Rating Scale for Depression (HAM-D, 17 items). 
The patients were informed about the study, and those 
who volunteered were included in the study. Patients with 
comorbid psychiatric disorders such as bipolar disorder, 
schizophrenia, or anxiety disorders were excluded from the 
study. Patients who were currently using psychotropic drugs, 
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displayed psychotic symptoms and mental retardation, or 
had comorbidity of psychiatric or neurological diseases were 
excluded from the study. The control group was composed of 
healthy individuals from the hospital staff and their relatives 
whose age and gender were similar to the patient groups and 
who had no physical or mental disorders. For each patient, 
an appointment at the Pamukkale University Faculty of 
Medicine Radiology clinic was made, and 1H-MRS scans 
were completed within 1 week of psychiatric evaluation.
The patients with depression were divided into two groups 
based on their HAM-D scores. Subjects that received 15 or 
lower HAM-D scores were determined to have a mild level 
of MDD (n = 21), and those with HAM-D scores that were 
higher than 15 points were determined to have a moderate 
level of MDD (n = 18). In total, 39 patients with MDD and 
16 healthy controls completed the study.
Approval for all procedures was obtained from the local 
ethics committee of Pamukkale University in accordance 
with the Declaration of Helsinki. Participants were informed 
about the study, and those who gave written consent were 
included.
The hamilton Rating Scale 
for Depression
The HAM-D is a 17-item, clinician-administered scale that 
was first published in 1960. It can be used to assess the 
severity of a patient’s depression; each item can be scored 
from 0 to 4.22 Akdemir et al23 have tested the validity and 
reliability of the Turkish version of the HAM-D. Total scores 
that are between 0 and 7 indicate no depression; scores that 
are between 8 and 15 indicate mild depression; scores that 
are between 16 and 28 indicate moderate depression; and 
scores that are greater than 29 indicate severe depression. 
The highest possible score is 53.
Proton magnetic resonance spectroscopy
The levels of various compounds in the right PFC were 
investigated using 1H-MRS (Figure 1). These compounds 
included NAA, Cr, and Cho, along with the NAA/Cr and 
Cho/Cr ratios. A 1H-MRS scan was conducted using a 1.5 
Tesla magnetic resonance scanner (GE Medical Systems, 
Milwaukee, WI, USA) and a standard head coil. The 
magnetic resonance protocol was conducted in the coronal 
plane using a T2-weighted fast spin-echo sequence with 
a 10-mm thickness and the following parameters: time of 
repetition (TR)/time of echo (TE), 3000/85; field of view, 
14; Matrix, 352 × 352; and Next, 1. However, MRS was 
measured with a single voxel (¹H-voxel). The 1H-MRS 
technique was directed at the right PFC region. To ensure 
that the relevant brain tissue was covered, the volume that 
was analyzed (volume of interest [VOI]) was manually 
and visually selected from the relevant regions that were 
mostly in the frontal lobe. The VOI that the neurochemical 
metabolites measured was 8 cm3. A chemical shift selective 
pulse24 was used to suppress the signals that originated 
from water. A point-resolved spectroscopy25 technique was 
then used to localize the volume of the spectroscopy (TR/
TE: 3000/144 and 3000/35 ms). As a result, short- and 
medium-duration TE spectra were obtained across the VOIs 
in regions of the right PFC, and these data were evaluated 
using GE’s spectral analysis program. The metabolite ratios 
were also evaluated.
Statistical analyses
Statistical analyses of the data were performed using SPSS 
15.0 software (IBM SPSS, Armonk, NY, USA). In addition 
to definitive statistical methods, a Mann–Whitney U test 
was used to compare the ages, the education levels, and 
the neurochemical metabolite levels of the depression and 
control groups. The relationship between HAM-D scores 
and neurochemical metabolites was analyzed with Pearson 
correlation analysis. Comparisons of neurometabolite 
values among the groups (mild MDD, moderate MDD, and 
healthy control group) were evaluated with nonparametric 
Kruskal–Wallis tests because the numbers of cases in the 
groups were not equal and because some values did not 
follow normal distributions. The significances of the findings 
Figure 1 The right prefrontal region: investigated the neurochemical metabolite levels.
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that were obtained from these tests were examined using 
Mann–Whitney U tests with Bonferroni corrections. A value 
of P , 0.016 was assumed to be significant.
Results
Thirty-nine patients with MDD and 16 healthy controls 
participated in the study. The ages and educational levels 
of the two groups were similar (P . 0.05). There were 
36 women and 3 men in the group with MDD. There were 
12 women and 4 men in the control group. No difference 
was found between the gender distributions of both groups 
(chi-square, P . 0.05). HAM-D scores were 15.80 ± 5.46 
(mean ± standard deviation [SD]) in all patients with MDD. 
No differences in the levels of NAA, Cr, Cho, NAA/Cr, and 
Cho/Cr were found between all the patients with MDD and 
the control group (Table 1).
The ages and the educational levels of the subjects in 
the mild MDD, moderate MDD, and control groups were 
similar (Table 2). The HAM-D scores of the moderate MDD 
group were significantly higher than those of the mild MDD 
group (respectively, 20.61 ± 4.04; 12.00 ± 2.35; z = 5.207, 
P , 0.001, Mann–Whitney U test). Differences were found 
in the NAA/Cr levels of the patients with mild MDD, 
the patients with moderate MDD, and the control group 
(Kruskal–Wallis test; Table 2). No differences in the levels 
of NAA, Cr, Cho, and Cho/Cr ratio were found among any 
of the three groups (Kruskal–Wallis test; Table 2). NAA/Cr 
levels in the moderate MDD group were lower than those 
of the control group (z = 2.478, P = 0.013; Mann–Whitney 
U tests with Bonferroni corrections). NAA/Cr levels in the 
moderate MDD group were lower than those of the mild MDD 
group, this difference was statistically close to significant 
levels (z = 1.930, P = 0.055, Mann–Whitney U tests with 
Bonferroni corrections). No significant difference between 
NAA/Cr levels in the mild MDD and control groups was 
found (z = 0.924, P = 0.356; Mann–Whitney U tests with 
Bonferroni corrections).
No correlation was found between neurochemical 
metabolite levels and HAM-D scores in patients with 
mild MDD, moderate MDD, and all depression groups 
(Pearson correlation analysis, for all P . 0.05), or between 
neurochemical metabolite levels and age (Pearson correlation 
analysis, for all P . 0.05).
Discussion
In our study, neurochemical metabolite levels in the PFC were 
investigated in first-episode MDD. The depressive symptom 
levels of the patients were mild and moderate. The patients 
were not using any psychotropic medication. No differences 
in neurochemical metabolite values were found between all 
patients with MDD and the control group. No correlation was 
found between neurochemical metabolite levels and HAM-D 
scores in the patients. NAA/Cr levels in patients with mild 
MDD were also observed to be similar to the control group. 
However, we found that the NAA/Cr levels in the patients 
with moderate MDD were lower than those of the control 
group. Our results suggest that the neurochemical metabolite 
level may be abnormal in moderate MDD. Our results lead 
us to think that depressive symptom intensity can be an 
important element affecting neuronal functions.
Some studies have reported that levels of neurochemical 
metabolites such as NAA, Cho, Cr, NAA/Cr, and Cho/Cr 
in the PFC are not different compared to healthy control 
groups.15,26,27 Nery et al28 found that the levels of NAA, Cr, 
and Cho in the dorsolateral PFC of MDD patients were not 
different compared to the healthy control group. In the Nery's 
study, the patients had a mean HAM-D score of 14.8 ± 6.9. The 
distribution of the severity of depression among this patient 
population was as follows: 30.8% of patients had mild MDD, 
61.5% had moderate MDD, and 7.7% had severe MDD. No 
correlations were found between the severity of the disease, 
the number of depressive episodes, and neurochemical 
metabolite levels. These results in our study suggest that 
neurochemical metabolite levels are not changed in MDD.
In contrast, there have been studies that have reported 
different results. Wang et al29 reported that levels of NAA/Cr 
and Cho/Cr in the dorsolateral PFC in MDD patients were 
lower than those of the healthy control group. Patients who had 
HAM-D scores of 18 and above, who did not use medication, 
and who had experienced their first depressive episode were 
evaluated in this study. The severity of depression and the 
results that were obtained are similar to the characteristics 
Table 1 Comparison of neurochemical metabolites in depression 
group and control group in prefrontal cortex
Variables Depression group 
(n = 39) 
Mean ± SD
Control group 
(n = 16) 
Mean ± SD
z* P**
Age 35.82 ± 12.93 31.31 ± 5.65 0.909 0.363
Education years  9.51 ± 4.65  9.43 ± 4.70 0.363 0.985
NAA 61.71 ± 17.08 66.37 ± 9.87 1.548 0.122
Cho 35.68 ± 7.41 35.31 ± 6.34 0.052 0.958
Cr 37.98 ± 9.11 38.75 ± 6.86 0.306 0.759
NAA/Cr  1.59 ± 0.33  1.73 ± 0.21 1.772 0.076
Cho/Cr  0.99 ± 0.25  0.94 ± 0.13 0.291 0.771
Notes: *Mann–Whitney U test; **P , 0.05 shows significance. 
Abbreviations: NAA, N-acetyl aspartate; Cho, choline; Cr, creatine; SD standard 
deviation; n, number.
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and results of our moderate MDD group. In another study, it 
was determined that the NAA/Cr ratios in the mediofrontal 
cortex were lower among patients with moderate MDD (the 
mean HAM-D score was 25.6 ± 5.0) compared with those 
in the healthy control group. Furthermore, NAA/Cr levels 
increased after treatment with antidepressants. This study 
also found evidence of a relationship between the severity 
of depression and NAA/Cr levels: the latter decreased as 
the former increased. There have been studies that have 
shown that neurochemical changes are affected by the 
duration of illness, chronicity, and the number of depressive 
episodes.30 In our study, we evaluated first-episode MDD. We 
determined that NAA/Cr levels were lower in moderate MDD. 
NAA is a compound recognized as a marker for neuronal 
integrity, viability, and/or function. Cr is used for our energy 
metabolism. Thus, our results indicate decreased neuronal 
integrity, vitality, and/or nonhealthy neuronal functions or 
abnormal cellular energy metabolism in moderate-level 
depression.
Studies in this area have also been done in children and 
the elderly. The studies in adolescents observed increases 
in Cho levels in the orbitofrontal cortex in patients with 
depression.31 In 10–16-year-old patients, it was found that 
Cho levels were higher in the left dorsolateral PFC, but 
unchanged in the right. It was found that levels of NAA and 
Cr were normal in the left and right dorsolateral PFC.32 In 
a study of children with depressive disorder, decreases in 
NAA levels in the medial PFC and decreases in the levels 
of NAA and Cho in the anterior cingulate cortex were 
found.33 It was reported that Cho levels were lower, and that 
levels of NAA and Cr in the dorsolateral PFC were similar 
to those of healthy control groups.34 In a study of elderly 
patients with MDD, it was found that patients who did not 
use antidepressant medication had low NAA/Cr ratios in the 
frontal white matter compared with the healthy controls. No 
differences between the patients who used medication and 
the healthy controls were observed. This study, in which the 
patients who were evaluated had HAM-D scores that were 
15 or higher, also reported that there was no relationship 
between the severity of depression, the age of disease onset, 
or neurochemical metabolite levels.35 It has been reported 
that NAA/Cr levels were lower36 and Cho/Cr levels were 
higher in patients with late-life depression.37 There have been 
studies showing increases in Cho levels and decreases or no 
change in NAA and Cr levels in children with MDD; other 
studies have shown that NAA levels are lower and Cho and 
Cr levels are higher in the elderly with MDD. Middle-aged 
patients with MDD were included in our study. A relationship 
between age and neurochemical metabolites was not found. 
Results suggest that neurochemical metabolite levels show 
similar changes in different age groups in MDD.
Structural and functional abnormalities have been 
detected in many brain areas in patients with MDD, 
including areas such as the PFC including the dorsolateral 
and ventrolateral regions, the hippocampus, the amygdala, 
and the basal ganglia. It has been suggested that the structural 
changes that occur in MDD are affected by factors such as 
age, family history, genetic factors, and the severity of the 
disease.38 Our results support the theory that the severity of 
depression may be linked to neurochemical metabolite levels. 
The PFC plays an essential role in mood regulation and 
cognitive functions, such as executive functions, in MDD. 
Planning and problem-solving may be impaired in patients 
with MDD.13,39 The relationships between neurochemical 
changes in the PFC and depressive symptomatology and 
cognitive function in MDD require further investigation.
Our study has some limitations. One is the lack of 
cases with severe, recurrent, and chronic MDD. Studies 
in such patients will contribute to our understanding of 
the relationship between neurochemical changes and the 
severity of depression. Another limitation of our study was 
that the scan was performed with a 1.5 Tesla MRS scanner 
Table 2 Comparison of neurochemical metabolites in mild MDD, moderate MDD, and control groups in prefrontal cortex
Variables Mild MDD (n = 21) Moderate MDD (n = 18) Control (n = 16) χ* P**
Mean ± SD Mean ± SD Mean ± SD
Age 33.80 ± 12.31 38.16 ± 13.59 31.31 ± 5.65 2.061 0.357
Education year 10.90 ± 3.70  7.88 ± 5.20  9.43 ± 4.70 3.573 0.168
NAA 63.67 ± 18.67 39.56 ± 11.04 66.40 ± 10.21 2.448 0.294
Cho 34.43 ± 8.15 37.26 ± 7.07 35.31 ± 6.34 1.891 0.389
Cr 36.63 ± 7.07 39.56 ± 11.04 38.75 ± 6.86 1.386 0.500
NAA/Cr  1.67 ± 0.23  1.49 ± 0.40  1.75 ± 0.20 7.552 0.023
Cho/Cr  0.95 ± 0.24  1.05 ± 0.25  0.94 ± 0.13 1.265 0.531
Notes: *Kruskal–Wallis test; **P , 0.05 shows significance. Bold text relates to a statistically significant result.
Abbreviations: NAA, N-acetyl aspartate; Cho, choline; Cr, creatine; DLPFC, dorsolateral prefrontal cortex; hAM-D, hamilton Rating Scale for Depression; MDD, major 
depressive disorder; mild MDD, hAM-D score #15; moderate MDD, hAM-D score .15; SD, standard deviation; n, number.
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using  single-voxel MRS at 3 Tesla and higher is more 
suitable for detecting levels of neurochemical metabolites. 
When evaluating such results, the characteristics of the 
device should be considered for further studies. In addition, 
absolute concentrations of neurochemical metabolite can be 
significantly influenced by gray matter and the cerebrospinal 
fluid content of the VOI.8 In addition, the features of 
depressive episode could be better defined in our study. 
These were the first depressive episodes of the patients and 
there was no medication. There were no psychotic findings. 
However, parameters such as the duration of depressive 
symptoms could be better defined. These limitations should 
be considered when evaluating the results of our study.
In conclusion, our results suggest that NAA/Cr levels 
are low in moderate-level MDD. Our results suggest that 
neuronal function and viability decrease in moderate MDD. 
There is a need to study the relationship severity of depression 
and neurochemical metabolites and the effects of severe 
depression on neuronal functions.
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